Enzalutamide/enzalutamide is produced and developed by which company?

Enzalutamide/Enzalutamide ( Enzalutamide) is developed and produced by Astellas (Astellas Pharmaceuticals). Astellas is a leading global pharmaceutical company focused on the research and development of innovative drugs covering multiple fields, including cancer treatment, immunology and neuroscience. Astellas was founded in 1923. After years of development, it has occupied a place in the global pharmaceutical industry, especially in the field of treatment of urological tumors, and its research and development results have continued to make breakthroughs.

Enzalutamide was first approved by the US FDA in 2012 and quickly became one of the core drugs for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Astellas has invested heavily in the research and development of this drug, and has verified its significant effect in the treatment of prostate cancer through multiple rounds of clinical trials. Enzalutamide has a unique mechanism of action. It inhibits androgen receptor activity and prevents androgens from stimulating prostate cancer cells, thereby slowing down cancer progression. It also has strong ability to penetrate the blood-brain barrier and can effectively control the occurrence of brain metastasis of prostate cancer.

Astellas' R&D team is also continuing to advance the application of enzalutamide in different prostate cancer types, promoting the widespread use of this drug worldwide. Thanks to Astellas's continuous innovation efforts, enzalutamide has been launched in many countries and regions, including the United States, Europe, Japan, etc., and has been approved by relevant drug regulatory agencies, making it one of the important drugs for the treatment of prostate cancer.

In general, Astellas not only promoted the marketization of enzalutamide with its strong R&D background, but also demonstrated its innovative strength in the global pharmaceutical industry in clinical research and drug promotion. As the drug continues to advance into clinical applications, it may bring hope to more prostate cancer patients in the future.

Reference materials:https://www.xtandi.com/